Xarelto Lawsuit Plaintiffs Gain Support Via Studies Connecting Anticoagulant To Risk Of Bleeding Episodes

March 30, 2016 – – BloodThinnerhelp.com reports on studies which may lend support to current plaintiffs’ arguments in lawsuits filed against Bayer and Janssen Pharmaceuticals regarding potential dangers of the anticoagulant drug Xarelto. Bayer and Janssen (a subdivision of Johnson & Johnson corporation) manufacture the new-generation blood-thinning drug. These studies being discussed appear to highlight a potential increase in the occurrence of stomach and eye bleeds among patients taking Xarelto. This potential risk appeared highest when patients were switching from a traditional blood thinner to the use of Xarelto.

One of the studies was published in an April 2015 issue of BMJ. In this study, researchers evaluated nearly 46,000 medical patients who were taking blood thinners, and noted that they could not rule out as much as a twofold increased risk of the occurrence of stomach bleeds among patients using Xarelto when compared to those taking warfarin, (a traditional blood thinner).

In another study, which was completed by Doctors John C. Hwang and Judy H. Hun, patients who had switched from using traditional blood thinner warfarin to Xarelto appeared to be at increased risk for suffering from vitreous hemorrhages or eye bleeds. In a vitreous hemorrhage, the bleed is located between the lens and retina of the eye. The doctors noted this occurrence among patients at their practice, which spurred them to further study the possible link.

Their findings were published in the June 2015 issue of Jama Ophthalmology, and noted that patients were at increased risk for these bleeds specifically while weaning off of warfarin and transferring to the use of Xarelto. They noted, “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.”

Each of these studies seem to lend support to arguments against the drug currently made by Xarelto lawsuit plaintiffs from across the United States. At this time, complaints filed regarding the drug are in the thousands. Over 2,800 of these lawsuit filings were transferred and consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL number 2592, while more than 600 others have been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.

Attorney Joseph Osborne understands how scary these allegations may be for patients currently using Xarelto, and is working to ensure that anyone who used Xarelto and suffered from complications that they believe were caused by their use of the drug will be given the opportunity to fully investigate their legal rights. Affected patients may be eligible for significant compensation gained through legal action. Those looking to explore their legal options more completely are being offered free Xarelto consultations at this time.

To ask questions regarding Xarelto lawsuits, or to request more information, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008978